Abstracts tagged "Lupus nephritis"

Abstract Number: 1844 • ACR Convergence 2025
Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
Paul Hoover¹, Rollin Leavitt², Jill Buyon³, Jennifer Anolik⁴, Jennifer Barnas⁵, Judith James⁶, Joel Guthridge⁶, Michelle Petri⁷, Betty Diamond⁸, Soumya Raychaudhuri¹, Nir Hacohen⁹, Anne Davidson¹⁰ and Arnon Arazi¹¹, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, MA, ³NYU Grossman School of Medicine, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵University of Rochester, Rochester, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸The Feinstein Institutes for Medical Research, Manhasset, NY, ⁹Broad Institute, Cambridge, MA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: In collaboration with the AMP-RA/SLE network, we identified disease-associated macrophages (D-Macs) in kidney biopsies from 155 patients with active lupus nephritis (LN) and 30…
Abstract Number: 1521 • ACR Convergence 2025
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad Rovin¹, William Pendergraft², Liz Lightstone³, Eric Daugas⁴, Richard Furie⁵, Theodore Omachi², Imran Hassan⁶, Elsa Martins⁷, Thomas Schindler⁷, Jay Garg², Luis Quintana⁸, Piotr Leszczyński⁹ and Ana Malvar¹⁰, ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁴Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Department of Nephrology, Hospital Clinic, Barcelona, Spain, ⁹Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…
Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Christopher Moore¹, Travis Drow², Peter Cook², Annaiz Grimm², Victoria DeVault-Nelson¹, Jennifer Mellen¹, Payam Zarin¹, Alaina Burgess¹, Maegan Hoover¹, Tingxi Guo¹, Brock McKinney², Noelle Dahl², Aesha Vakil², Brian Christin³, Gene Uenishi¹, Tiffany Chen¹, Alberto Del Rio-Espinola⁴, David Rawlings² and Tom Wickham¹, ¹GentiBio, Cambridge, ²SCRI, Seattle, ³GentiBio, Seattle, ⁴GentiBio, Basel, Switzerland
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
Abstract Number: 0642 • ACR Convergence 2025
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Paola Vidal Montal¹, Javier Narváez², Aina Fabregat³, Iñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Andrea Hernández-martín⁶, Clara Moriano⁷, Maria Garcia-Villanueva⁸, Sandra Garrote Corral⁹, Sergi Heredia¹⁰, Julia Martínez Barrio¹¹, Júlia Bernardez Moreno¹², Paloma Vela Casasempere¹³, Beatriz Tejera Segura¹⁴, Leyre Riancho¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Maria Piqueras García¹⁸, Beatriz Frade Sosa¹⁹, José Gomez-Puerta²⁰, Consuelo Ramos Giraldez²¹, Tarek Salman Montes²², María Galindo-Izquierdo²³, EVA GLORIA TOMERO MURIEL²⁴, Jaime calvo²⁵, Jorge Juan Fragío Gil²⁶, Marta De la Rubia Navarro²⁷, Berta Magallares²⁸ and Irene Altabás-González²⁹, ¹Bellvitge University Hospital, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁵Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁶Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁷Hospital León, LEON, Castilla y Leon, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹Hospital Ramón y Cajal, Madrid, ¹⁰Hospital Moisès Broggi, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁴Hospital Insular de Gran Canaria, Las palmas, Spain, ¹⁵Hospital de Sierrallana, Torrelavega, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Servicio Murciano de Salud, Murcia, Spain, ¹⁹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ²²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²³Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁴Hospital Universitario de la Princesa, Madrid, Spain, ²⁵Hospital de Araba, Vitoria, Spain, ²⁶Hospital General Universitario, Valencia, Spain, ²⁷Hospital de La Fe, Valencia, ²⁸Hospital de Sant Pau, Bareclona, ²⁹Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: The newly published ACR guidelines recommend initiating triple therapy for all patients with proliferative lupus nephritis (LN). While belimumab (BEL) has demonstrated efficacy in…
Abstract Number: 0840 • ACR Convergence 2025
Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
Alessandra Ida Celia¹, Daksh Saksena², CHEN-YU LEE³, Carla Guthridge⁴, Wade DeJager⁵, Rufei Lu⁴, Judith James⁴, Jill Buyon⁶, Michelle Petri⁷, Joel Guthridge⁴, Brad Rovin⁸ and Andrea Fava³, ¹Sapienza University of Rome, Rome, Italy, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Urine collects the byproducts of kidney biology and has emerged as a valuable, noninvasive source of molecular information that reflects intrarenal pathology. In lupus…
Abstract Number: 2438 • ACR Convergence 2025
SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Ahmad Alomari¹, Asim Khanfar², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²Rochester General Hospital, Rochester, NY, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease linked to significant morbidity, including pulmonary hypertension (PH). While SGLT2 inhibitors are known for cardiovascular…
Abstract Number: 1841 • ACR Convergence 2025
Differential metabolomic signatures along lupus nephritis spectrum
Mariana Jiménez Tirado¹, karina santana², Jiram Torres Ruiz³, Jennifer Tiaré Balderas Miranda⁴, Diana Gómez-Martín⁵, José Carlos Páez Franco⁶, Nancy R Mejía Domínguez⁷, Hilda Sánchez Vidal⁶ and Imelda Cecilia Zarzoza Mendoza⁸, ¹Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Ciudad de México, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico, ⁴Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁵INCMNSZ, Mexico city, Federal District, Mexico, ⁶Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Distrito Federal, Mexico, ⁷Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁸Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico
Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…
Abstract Number: 1520 • ACR Convergence 2025
Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Bahtiyar Toz¹, Himanshu Vashistha² and Richard Furie³, ¹Zucker School of Medicine at Hofstra/ Northwell, Queens, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Biologic treatments for lupus nephritis (LN) have improved short-term outcomes. Obinutuzumab (OBI), an anti-CD20 monoclonal antibody, demonstrated efficacy in the NOBILITY and REGENCY trials;…
Abstract Number: 0945 • ACR Convergence 2025
Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
Jorge Romo-Tena¹, Luz Blanco², Shuichiro Nakabo³, Victoria Hoffman⁴, Norio Hanata⁵, Mingzeng Zhang², Carmelo Carmona-Rivera⁵, Eduardo Patino-Martinez⁶, Dillon Claybaugh², Zu-Xi Yu² and Mariana Kaplan⁵, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²NIH, Bethesda, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶NIH/NIAMS, Bethesda, MD
Background/Purpose: Nerve injury-induced protein-1 (Ninj1) is an adhesion molecule that plays various roles in immune and stromal cells, including the modulation of inflammation and a…
Abstract Number: 0639 • ACR Convergence 2025
Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
Vanesa Calvo-Río¹, Lara Sánchez Bilbao¹, Carmen Secada-Gómez¹, Paúl Hernández Velasco², Celia González-García³, Enrique Morales⁴, María Galindo-Izquierdo⁵, Sebastián Sandoval-Moreno⁶, Josefina Cortés-Hernández⁷, César Antonio Egües Dubuc⁸, Niccolo Viveros-Pérez⁹, María Caeiro¹⁰, Adrián Mayo-Juanatey¹¹, Miriam Retuerto Guerrero¹², María Camila Osorio-Sanjuan¹³, Luis Sala¹⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Nephrology, Hospital Universitario ¹² de Octubre, Madrid. Spain, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁴Nephrology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ⁶Hospital Universitario Vall D'Hebron, Barcelona, Spain, ⁷Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ⁸Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ⁹Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ¹⁰Centro Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ¹²Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, ¹³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁴Hospital Universitario de Torrejón, Madrid, Spain
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) affecting to 40-60% of SLE. End-stage renal disease (ESRD) occurs in up…
Abstract Number: 0839 • ACR Convergence 2025
Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking
Qiuyu Jing¹, Qiang Li², Chiu Wai Shirley Chan³, Weixin Chen⁴, Fung Yu Nick choi⁴, Iris Tang⁵, Chak Sing Lau⁶, Heidi Ling⁶, Jason Wong⁷ and Philip Li², ¹Center for Oncology & Immunology, Hong Kong, Hong Kong, ²Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ⁶The University of Hong Kong, Hong Kong, Hong Kong, ⁷School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hing Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), lacks reliable non-invasive biomarkers for early detection and monitoring. This study investigates plasma…
Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Matt Makara, Casey Hogan
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
Abstract Number: 2427 • ACR Convergence 2025
Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease
Sepehr Taghavi¹, Ines Silva², Jacob Vasquez³, Vasileios Kyttaris⁴, Tyler O'Malley⁵ and Mike Nerenberg⁶, ¹Exagen Inc, Escondido, CA, ²Exagen, Carlsbad, CA, ³Exagen, Inc., Vista, CA, ⁴Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ⁵Exagen, Vista, CA, ⁶Exagen, DEL MAR, CA
Background/Purpose: Early detection of renal involvement in diabetic kidney disease (DKD) and lupus nephritis (LN) is critical but remains challenging. Conventional renal biomarkers (serum creatinine,…
Abstract Number: 1836 • ACR Convergence 2025
Emerging Role of B Cell Subtype-Specific Intracytoplasmic Toll-Like Receptor Expression and Serum Eotaxin as Biomarkers in Lupus Nephritis
Jennifer Tiaré Balderas Miranda¹, Yatzil Reyna Juárez², Beatriz Alcalá-Carmona³, Nancy R Mejía Domínguez⁴, María José Ostos Prado³, José Luis Maravillas-Montero⁵, Fabiola Cassiano-Quezada⁶, Guillermo Juárez Vega⁴, karina santana⁷, Jiram Torres Ruiz⁸ and Diana Gómez-Martín⁹, ¹Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ²Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ³Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁴Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Tlalpan, Distrito Federal, Mexico, ⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁷INCMNSZ, Ciudad de México, Federal District, Mexico, ⁸INCMNSZ, Mexico, Federal District, Mexico, ⁹INCMNSZ, Mexico city, Federal District, Mexico
Background/Purpose: B cells play an essential role in lupus nephritis (LN) pathogenesis. However, abnormalities in specific subtypes like age-associated B cells (ABCs) and double negative…
Abstract Number: 1517 • ACR Convergence 2025
The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Aijing Liu¹, Fei Chang² and Qiuhong Xu¹, ¹Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ²Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)
Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].